Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday, Marketbeat Ratings reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 38.50% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. UBS Group upped their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Wedbush restated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Stock Down 3.7%

Shares of NASDAQ:ORKA opened at $86.64 on Thursday. The company’s 50 day moving average price is $96.79 and its two-hundred day moving average price is $75.32. Oruka Therapeutics has a 12-month low of $14.89 and a 12-month high of $115.51. The firm has a market cap of $5.74 billion, a PE ratio of -42.71 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, research analysts expect that Oruka Therapeutics will post -2.42 EPS for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Klein sold 2,452 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total transaction of $234,680.92. Following the completion of the sale, the chief executive officer owned 923,128 shares of the company’s stock, valued at $88,352,580.88. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. This represents a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 122,950 shares of company stock valued at $11,528,806 in the last quarter. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $474,916,000. Remedium Capital Partners LLC lifted its position in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after purchasing an additional 13,247 shares during the period. Perceptive Advisors LLC lifted its position in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after purchasing an additional 208,480 shares during the period. Jupiter Topco LLC bought a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $130,968,000. Finally, Avidity Partners Management LP increased its stake in shares of Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after acquiring an additional 100,000 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $165 price target, implying substantial potential upside from the referenced $89.93 level. Tickerreport analyst rating article
• Positive Sentiment: HC Wainwright also reaffirmed its “buy” rating and assigned a $120 price target, indicating continued analyst confidence in Oruka’s pipeline and valuation. StreetInsider analyst rating article
• Positive Sentiment: Oruka reported encouraging Week 28 results from the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 responses increased to 71.4% and PASI 90 responses to 87.3%, despite no additional dosing after Week 4, suggesting durable and deepening treatment effects. Oruka EVERLAST-A Week 28 results
• Positive Sentiment: Placebo-crossover patients achieved PASI 90 and PASI 100 response rates comparable to patients initially treated with ORKA-001, while the therapy continued to show a favorable safety and tolerability profile. Additional EVERLAST-A data are expected in December 2026, with EVERLAST-B results expected in the fourth quarter. MarketScreener trial results
• Negative Sentiment: Oruka shares fell after the Week 28 release despite improving psoriasis responses. The reaction suggests investors may have already anticipated strong data, or may be focused on the need for additional validation from upcoming 52-week and follow-on trial results. Yahoo Finance market reaction

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.